Savara Inc
$ 6.37
1.11%
04 Dec - close price
- Market Cap 1,281,847,000 USD
- Current Price $ 6.37
- High / Low $ 6.45 / 6.18
- Stock P/E N/A
- Book Value 0.45
- EPS -0.53
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.79 %
- 52 Week High 6.61
- 52 Week Low 1.89
About
Savara Inc. is a biopharmaceutical company based in Austin, Texas, specializing in the development of innovative therapies for rare lung diseases. Committed to addressing significant unmet medical needs in respiratory health, Savara's robust pipeline features several promising candidates targeting various orphan indications. By leveraging advanced scientific research and maintaining a patient-centric approach, Savara is well-positioned to make meaningful impacts in the treatment of lung diseases, establishing itself as a pivotal player in this niche therapeutic landscape.
Analyst Target Price
$10.31
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-13 | 2025-05-07 | 2025-03-05 | 2024-11-07 | 2024-08-12 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 | 2023-05-15 | 2023-03-30 |
| Reported EPS | -0.14 | -0.14 | -0.12 | -0.13 | -0.1145 | -0.12 | -0.11 | -0.09 | -0.1 | -0.07 | -0.07 | -0.07 |
| Estimated EPS | -0.13 | -0.12 | -0.128 | -0.114 | -0.11 | -0.11 | -0.1 | -0.1 | -0.07 | -0.08 | -0.07 | -0.07 |
| Surprise | -0.01 | -0.02 | 0.008 | -0.016 | -0.0045 | -0.01 | -0.01 | 0.01 | -0.03 | 0.01 | 0 | 0 |
| Surprise Percentage | -7.6923% | -16.6667% | 6.25% | -14.0351% | -4.0909% | -9.0909% | -10% | 10% | -42.8571% | 12.5% | 0% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SVRA
2025-10-23 02:02:06
This article is a stockholder alert announcing that Bronstein, Gewirtz and Grossman, LLC is informing Savara Inc. investors who have incurred losses of their opportunity to lead a class action lawsuit. The nature of the article is a legal notice regarding potential litigation. It suggests that investors meeting certain criteria may participate in the lawsuit against Savara Inc.
2025-10-23 02:02:06
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit opportunity for investors of Savara Inc. (SVRA) who experienced losses. The law firm is seeking to identify investors who incurred losses and may be eligible to lead the lawsuit. This alert suggests potential legal action against Savara Inc.
2025-10-23 02:02:06
This article is a legal alert from Levi & Korsinsky, LLP, notifying investors of Savara Inc. (SVRA) about a securities class action lawsuit. Investors who purchased Savara securities between November 9, 2023, and February 20, 2024, are encouraged to contact the law firm by November 7, 2025, to discuss their rights. The lawsuit alleges that Savara made materially false and/or misleading statements and failed to disclose critical information concerning its product, molgramostim.
2025-10-23 02:02:06
This article is a placeholder, likely an error page, requesting a human confirmation. It presents no actual news content regarding Levi & Korsinsky or Savara Inc. and instead only displays a captcha-like prompt.
2025-10-23 02:02:06
This article is a placeholder, only containing introductory text to verify human interaction. It mentions a new class action lawsuit against Savara Inc. by Shareholders SueWallSt.
2025-10-23 02:02:06
A class action lawsuit has been filed against Savara Inc. (SVRA) on behalf of investors who purchased securities between November 9, 2023, and February 13, 2024. The lawsuit alleges that Savara made false and/or misleading statements and failed to disclose material adverse facts regarding its lead product candidate, molgramostim. Investors who suffered losses are encouraged to contact The Gross Law Firm for more information.
